Observational studyCritical care medicine2018
Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.
Observational study in Critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.Communications biology · 2021Pooled it
- Pancreatic Stone Protein in Co-Evaluation With QSOFA and News2 for Early Sepsis Detection at the Emergency Department.Shock (Augusta, Ga.) · 2026Trial
- qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial.Critical care (London, England) · 2024Trial
- Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial.Scandinavian journal of trauma, resuscitation and emergency medicine · 2019Trial
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.Diagnostics (Basel, Switzerland) · 2025Article
- Soluble Urokinase Plasminogen Activator Receptor: A Promising Biomarker for Mortality Prediction Among Critical ED Patients.International journal of molecular sciences · 2025Article
- Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.Cureus · 2024Article
- Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.European journal of preventive cardiology · 2024Article
- Article
- Risk Prediction Models for Hospital Mortality in General Medical Patients: A Systematic Review.American journal of medicine open · 2023Article
- Predicting acute clinical deterioration with interpretable machine learning to support emergency care decision making.Scientific reports · 2023Article
- Challenges facing the clinical adoption of a new prognostic biomarker: a case study.BioSocieties · 2023Article
- Circulating suPAR associates with severity and in-hospital progression of COVID-19.European journal of clinical investigation · 2022Observational
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients.Journal of clinical medicine · 2022Article
- [Prognostic power of soluble urokinase plasminogen activator receptor (suPAR) for short-term mortality in patients seen in Emergency Departments due to infections].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Observational
- Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making.Biomarker insights · 2022Article
- Article
- Predictive Performance of the NEWS‒Lactate and NEWS Towards Mortality or Need for Critical Care Among Patients with Suspicion of Sepsis in the Emergency Department: A Prospective Observational Study.Open access emergency medicine : OAEM · 2022Article
- Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update.Caspian journal of internal medicine · 2022Article
- suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department.BMC emergency medicine · 2021Observational
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSoluble urokinase plasminogen activator receptor is a prognostic biomarker associated with critical illness, disease progression, and risk of mortality. We aimed to evaluate whether soluble urokinase plasminogen activator receptor adds prognostic value to a vital sign-based score for clinical monitoring of patient risk (National Early Warning Score) in acute medical patients.
designRegistry-based observational cohort study of consecutively admitted acute medical patients.
settingThe Acute Medical Unit, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. PATIENTS: Acute medical patients admitted between November 18, 2013, and September 30, 2015.
interventionsNone. MEASUREMENTS AND MAIN
resultsOf 17,312 included patients, admission National Early Warning Score was available for 16,244 (93.8%). During follow-up, 587 patients (3.4%) died in-hospital, 859 (5.0%) within 30 days, and 1,367 (7.9%) within 90 days. High soluble urokinase plasminogen activator receptor was significantly associated with in-hospital-, 30-day-, and 90-day mortality within all National Early Warning Score groups, in particular in patients with a low National Early Warning Score; for 30-day mortality, mortality rate ratios ranged from 3.45 (95% CI, 2.91-4.10) for patients with National Early Warning Score 0-1, to 1.86 (95% CI, 1.47-2.34) for patients with National Early Warning Score greater than or equal to 9 for every doubling in soluble urokinase plasminogen activator receptor (log2-transformed). Combining National Early Warning Score, age, and sex with soluble urokinase plasminogen activator receptor improved prediction of in-hospital-, 30-day-, and 90-day mortality, increasing the area under the curve (95% CI) for 30-day mortality from 0.86 (0.85-0.87) to 0.90 (0.89-0.91), p value of less than 0.0001, with a negative predictive value of 99.0%.
conclusionsThe addition of soluble urokinase plasminogen activator receptor to National Early Warning Score significantly improved risk prediction of both low- and high-risk acute medical patients. Patients with low National Early Warning Score but elevated soluble urokinase plasminogen activator receptor had mortality risks comparable to that of patients with higher National Early Warning Score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.